MIA in the spotlight at ASCO virtual conference
30 May 2020
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting has gone virtual, with researchers from MIA once again in the spotlight. Usually attended by over 40,000 professionals, ASCO’s Annual Meeting showcased global advances in research and treatment, all of which impact patient outcomes.
Headlining MIA’s contribution at ASCO 20 Virtual was Dr Ines Silva, a clinical fellow and post-doctoral researcher at MIA, who was awarded the prestigious Bradley Stuart Beller Endowed award for best abstract.
Dr Silva’s abstract related to an oral presentation delivered virtually at ASCO, assessing the impact of Ipilimumab-based immunotherapy in patients with metastatic melanoma whose disease had already proven resistant to anti-PD1 monotherapy.
The multicentre retrospective study involved 355 patients with Stage III or Stage IV melanoma whose cancer had progressed or recurred despite having anti-PD1 monotherapy. 46% of these patients were then treated with ipilimumab alone, with 54% receiving combination ipilimumab and anti-PD1 therapy.
In patients who received the follow up combination therapy, there was a higher response rate (32%) as well as longer progression free survival (25% at 12 months) and overall survival (58% at 12 months) compared to IPI alone. Importantly, IPI+anti-PD1 was not associated with more severe side effects than IPI monotherapy.
Dr Silva and the MIA team created clinical predictive models to help identify the patients who will benefit from these treatments.
‘It was an honour to deliver the oral presentation virtually at ASCO 20 Virtual,’ said Dr Silva. ‘Although we weren’t together physically, still being able to share insights and learnings globally was vitally important in ensuring we continue on our path to saving more lives from melanoma.’
Also awarded at ASCO 20 Virtual were Dr Adriana Hepner and Dr Lauren Brown who received merit awards for abstracts submitted. Overall, MIA researchers and clinicians contributed to 21 abstracts featured at ASCO.
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way in changing the treatment landscape for melanoma patients,’ MIA Co-Medical Director Professor Georgina Long said.
‘Our mission is zero deaths from melanoma, and by collaborating with our colleagues on the world stage we are confident we are on track to reach that goal within our lifetime,’ added MIA Co-Medical Director Professor Richard Scolyer.
Register to view Dr Silva's video and slides here: Dr Silva presentation
See the ASCO 20 Virtual Program here: ASCO 20 Virtual
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.